News

Video

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

Author(s):

Robert Z. Orlowski, MD, PhD

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.

Related Videos
Rahul Banerjee, MD, FACP
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Sagar Lonial, MD, FACP
Shyam A. Patel, MD, PhD
Amitkumar Mehta, MD
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Related Content
Nizar Bahlis, MD
September 27th 2024

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Shyam A. Patel, MD,PhD
September 27th 2024

Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens School of Medicine
September 26th 2024

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

Chip Baird
September 25th 2024

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enrollment